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Abstract
Background: There is no consensus regarding the impact of stenting on long-term endothelial function. There have been 
reports of increased endothelial dysfunction with sirolimus-eluting stents as compared to bare metal stenting (BMS).
Objective: This study aims to assess the impact of BMS and the effect of oral sirolimus on endothelial function.
Methods: Forty-five patients were randomized into three groups: BMS + high-dose oral sirolimus (initial dose of 15 mg, 
followed by 6 mg/day for four weeks); BMS + low-dose sirolimus (6 mg followed by 2 mg daily for four weeks); and BMS 
without sirolimus. Changes in vasoconstriction or vasodilation in a 15 mm segment starting at the distal stent end in 
response to acetylcholine and nitroglycerin were assessed by quantitative angiography. 
Results: The groups had similar angiographic characteristics. The percent variation in diameter in response to 
acetylcholine was similar in all groups at the two time points (p = 0.469). Four hours after stenting, the target segment 
presented an endothelial dysfunction that was maintained after eight months in all groups. In all groups, endothelium-
independent vasomotion in response to nitroglycerin was similar at four hours and eight months, with increased target 
segment diameter after nitroglycerin infusion (p = 0.001).
Conclusion: The endothelial dysfunction was similarly present at the 15 mm segment distal to the treated segment, at 4 
hours and 8 months after stenting. Sirolimus administered orally during 4 weeks to prevent restenosis did not affect the 
status of endothelium-dependent and independent vasomotion. (Arq Bras Cardiol 2012;98(4):290-299)
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assessment of improved technology, affecting both the need 
and type of polymer and the type of drug10-16.
The primary endpoint of this study was to measure the 
degree of change on endothelial function following BMS 
implantation and evaluate the effect of oral sirolimusto 
prevent in-stent intimal hyperplasia on the BMS endothelial 
function response.
Methods
From April 2003 to March 2004, patients treated with 
percutaneous coronary intervention (PCI) with BMS were 
enrolled in this study. Inclusion criteria were coronary artery 
disease and clinical indication for elective coronary stenting, 
target vessel reference diameter ≥ 2.5 mm, and successful 
interventional procedure according to the AHA/ACC/SCAI 2005 
Guideline Update for PCI17. An Express® stent (Boston Scientific 
Corp, Natick, MA) was used in all interventions. The Research 
Ethics Committee at the Universidade Federal de São Paulo 
approved the protocol. The study was conducted in accordance 
with the provisions of the Declaration of Helsinki.
Exclusion criteria were impossibility of discontinuing the 
use of nitrate or calcium channel blockers in the 48 hours 
Introduction
Despite the greater effectiveness and safety of stenting 
as compared to balloon angioplasty, there is no consensus 
regarding the effect of stenting on endothelial-dependent 
vasomotricity. Caramori et al1 have observed more pronounced 
long-term endothelial dysfunction with coronary artery 
stenting than balloon angioplasty or directional atherectomy. In 
contrast, Maier et al2 reported preserved endothelial function 
in segments located proximally and distally to the stent.
The advent of drug-eluting stents (DES) has underscored the 
importance of this topic especially after reports of worsened 
endothelial dysfunction as compared to bare metal stenting 
(BMS) 3-6. Worsened endothelial dysfunction and greatly 
impaired endothelial stent strut coverage have been strongly 
related to late and very late DES thrombosis, among other 
factors7-9. In fact, this serious DES safety issue has led to 
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before angioplasty, coronary spasm after stenting, uncontrolled 
hypertension, second and third-degree atrioventricular block, 
severe aortic stenosis, pregnancy, chronic obstructive pulmonary 
disease, acute or chronic renal failure (creatinine > 1.5 mg/dL), 
functional class III and IV heart failure, acute or chronic infectious 
disease, left main coronary artery shorter than 10 mm.
Patients were randomized into three groups. Group 1 (BMS 
+ high-dose sirolimus) received an initial sirolimus dose of 15 
mg, followed by 6 mg/day during four weeks. Group 2 (BMS 
+ low-dose sirolimus) received an initial sirolimus dose of 6 
mg, followed by 2 mg daily during four weeks. Group 3 (BMS 
without sirolimus therapy) was the control group. Sirolimus 
was administered orally to patients in groups 1 and 2, with 
the initial dose given on the day before PCI. In these patients, 
sirolimus whole blood concentration (WBC) was monitored 
weekly with the aim of achieving a concentration of 10-20 
ng/mL and 5-10 ng/mL, respectively, in each group.
Study protocol and evaluation of vasomotor function
Two evaluations were performed in the first four hours after 
stent implantation and the second eight months later. A 15-
mm segment starting at the distal stent border was arbitrarily 
defined as the target segment. This segment was analyzed 
by off-line quantitative coronary angiography (QCA) and 
intravascular ultrasound (IVUS). PCI and IVUS were performed 
using standard techniques.
During intracoronary infusion of acetylcholine, heart rate 
and frequency, blood pressure, changes in ST-T segment, 
and oxygen saturation (digital oximetry) were continuously 
monitored. Acetylcholine was infused for 2 minutes with a 
syringe pump (IP 680, Samtronic do Brasil, São Paulo, Brazil) at 
1.25 mL/min and 0.625 mL/min into the left and right coronary 
arteries, respectively, in the following sequence: control (saline 
0.9%); incremental doses of acetylcholine (Ach): 10-6 mol/L 
(0.036 mg/mL), 10-5 mol/L (0.36 mg/mL), and 10-4 mol/L (3.6 
mg/mL); recontrol (0.9% saline); and 300 mg nitroglycerine.
Endothelial dysfunction was arbitrarily defined as less than 
5% vasodilation or any degree vasoconstriction.
Quantitative coronary analysis (QCA)
Off-line quantitative coronary angiography was carried out 
with the Cardiovascular Measurement System 5.0, Medis, 
Neunen, The Netherlands. The target segment diameter was 
measured during the control and other stages. The percent 
variation in target segment mean diameter as compared to the 
control measurement was the end-point used to determine 
endothelium-dependent (response to acetylcholine) and 
independent (response to nitroglycerin) vasomotion. An 
observer who was blinded to the group to which the patient 
had been randomized performed the measurements.
Intracoronary ultrasound (IVUS)
IVUS imaging was performed immediately after stent 
placement and following intracoronary nitroglycerine 
administration. The measurements were performed 
according to the recommendations of the American College 
of Cardiology and the European Society of Cardiology18. The 
images were obtained using a mechanical system (Galaxy II, 
Boston Scientifc Corp, Natick, MA). A transducer positioned 
at least 15 mm distally from the stent was automatically pulled 
back at a constant speed of 0.5 mm/s. Only artifact-free 
images were analyzed. Atlantis SRTM Pro 40 MHz or Ultra 
Cross 30 MHz (Boston Scientific Corp, Natick, MA) catheters 
were used. To correct variability resulting from the use of 
various catheters, calibration equations were applied19. Off-
line analysis to determine cross-sectional areas and derived 
volumes was performed with appropriate software (QIVA, 
Pie Medical BV, Maastricht, The Netherlands). All data were 
evaluated by the investigator in chief and reviewed by two 
additional observers blinded to the groups to which the patient 
had been randomized.
Statistical analysis
The sample size was calculated based on the in-stent 
restenosis study primary endpoint which was the IVUS stent 
obstruction volume at eight-month follow-up. The calculation 
led to 45 patients (15 patients per group) in order to provide 
80% statistical power (b = 0.2) to detect a 40% reduction in 
the primary end-point (from 30 ± 15% in the control group 
to 18 ± 15% in the two drug groups), with a 5% probability 
of type 1 error (a = 0.05). Therefore, for the endothelial 
dysfunction assessment, the study individuals were just the 
handy population target.
Continuous variables were expressed as mean ± standard 
deviation (SD). To study the behavior of numeric variables for 
each group in time, taking into consideration the association 
between the measurements obtained for each single patient, 
repeated measures analysis of variance (ANOVA) was 
employed. To investigate the association between continuous 
variables, dispersion graphs were plotted and Pearson’s 
linear correlation was calculated. Categorical variables were 
expressed as percent values. The association between the 
variables of interest was verified using Fisher’s exact test. 
Significance was established as p < 0.05. 
Results
Baseline characteristics and clinical events during follow-up
From the 45 patients randomized, 39 fulfilled the inclusion 
criteria for the vasomotricity study protocol. Six were excluded 
from the study: three for having severe coronary artery spasm 
after stenting, two for having short left main coronary artery 
and one patient withdrew informed consent. 
Thirty-nine patients underwent endothelial function testing 
four hours after stenting and 36 patients eight months later. 
Three patients were not available for the second evaluation: 
two died suddenly of an unknown cause four months after 
PCI. The third patient was excluded due to severe in-stent 
restenosis associated with severe chest pain during the 
coronary angiography. There were no significant differences 
between the groups in terms of indication for angioplasty, 
treated artery and type of lesion according to the ACC/AHA/
SCAI 2005 Guideline Update for Percutaneous Coronary 
Intervention classification17. Baseline patient’s clinical 
characteristics are in Table 1.
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Table 1 - Baseline Patient’s Characteristics, Quantitative Angiographic and IVUS data
Group 1
(10-20 ng/ml)
Group 2
(5-10 ng/ml)
Group 3
(control)
Age (years) 55 ± 8 52 ± 7 54 ± 10
Gender (M/F) 9/6 (60% / 40%) 10/5 (67% / 33%) 9/6 (60% / 40%)
Medical History
Diabetes mellitus 5 (33%) 5 (33%) 4 (31%)
Current smoker 11 (73%) 10 (67%) 5 (38%)
Hypertension 14 (93%) 14 (93%) 13 (100%)
Hypercholesterolemia 5 (33%) 5 (33%) 6 (46%)
Prior MI 2 (13%) 2 (13%) 5 (38%)
Clinical presentation
Stable Angina 6 (40%) 4 (27%) 9 (69%)
Unstable Angina 2 (13%) 2 (13%) 3 (31%)
Recent MI 4 (27%) 9 (60%) 3 (31%)
Treated Vessel
LAD 8 (53%) 7 (47%) 7 (54%)
Left Circumflex 1 (7%) 1 (6%) 1 (8%)
RCA 6 (40%) 7 (47%) 5 (38%)
Lesion Type 
A/B1 9 (60%) 7 (47%) 10 (77%)
B2/C 6 (40%) 8 (53%) 3 (23%)
Baseline Angiography
Lesion length (mm) 16.81 ± 4.33 15.95 ± 7.17 13.19 ± 4.85
Reference diameter (mm) 2.8 ± 0.55 2.98 ± 0.59 2.95 ± 0.34
MLD (mm) 1.10 ± 0.25 1.14 ± 0.45 1.27 ± 0.38
Diameter stenosis (%) 60.70 ± 10.06 61.05 ± 13.73 56.18 ± 14.98
Post procedure Angiography
Reference diameter (mm) 3.17 ± 0.43 3.22 ± 0.45 3.17 ± 0.05
Acute gain (mm) 1.76 ± 0.42 1.78 ± 0.39 1.68 ± 0.14
In-Stent MLD (mm) 2.86 ± 0.38 2.92 ± 0.52 2.96 ± 0.52
In-Stent Diameter stenosis (%) 10.2 ± 10 7 ± 7 6.7 ± 6.6
8-Months Angiographic F-Up*
Reference diameter (mm) 2.91 ± 0.4 3.01 ± 0.53 2.78 ± 2.31
In-Stent MLD(mm) 2.04 ± 0.74 2.15 ± 0.74 1.62 ± 0.50
In-stent Diameter stenosis (%) 31.4 ± 21.9 30.8 ± 18.5 35.6 ± 23.3
I-stent Late loss (mm) ‡ 0.83 ± 0.7 0.78 ± 0.64 1.34 ± 0.45
Binary Restenosis 1(7%) 4(27%) 5(42%)
8-Months IVUS Follow-up*
Stent volume (mm3) 214.4 ± 69.4 212 ± 87.4 153 ± 91.1
Lumen volume (mm3)& 138.21 ± 63 142.34 ± 72.7 68.8 ± 45
NIH volume (mm3) 66 ± 56.3 65.6 ± 41.4 66.4 ± 57.9
Obstruction volume (%)§ 35.3 ± 22.6 33.2 ± 16.5 54.6 ± 16.0
Data are presented as number (relative percentages) or mean value ± SD; 8-month follow-up available for 12 patients in group 1 due to 1 death in 
the fourth month. ‡ p 0,027 G1;G2 vs G3 / & p 0.017 G1; G2 vs G3 / § p 0.015 G1; G2 vs G3. ANOVA-BONFERRONI; MI - Myocardial infarction; 
NIH - Neointimal hyperplasia; LAD - Left anterior descending artery; RCA - Right coronary artery; M.L.D - Minimum luminal diameter; A/B1 & B2/C - 
Classification of ACC/AHA.
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Baseline and 8-Month Angiographic and IVUS Follow-Up 
Data
Groups were well matched with respect to baseline 
quantitative angiographic and IVUS data (Table 1). At follow-
up, percent diameter stenosis and minimal lumen diameter 
were not different among groups, at the same time in-stent 
late lumen loss was significantly lower in groups 1 and 2 
than in the control group 3 (p = 0.027). Additionally, IVUS 
analysis demonstrated that obstruction volume was lower in 
groups 1 and 2 than in group 3 (p=0.015). There were no 
significant differences between groups 1 and 2 with regard to 
angiographic and IVUS parameters at follow-up. 
Response to acetylcholine
In group 1, vasomotor function was evaluated in 14 patients 
at four hours after stenting. Twelve patients underwent a 
second evaluation eight months later. Response to high-dose 
acetylcholine (10-4 mol/L) was -2.36 ± 10.86% and -4.63 
± 10.53% vasoconstriction at four hours and eight months, 
respectively (p = 0.469). In group 2, both evaluations were 
performed in 12 patients. Response to high-dose acetylcholine 
(10-4 mol/L) was -5.98 ± 12.62% and -4.42 ± 14.64% 
vasoconstriction at four hours and eight months, respectively (p 
= 0.469). In group 3, four-hour evaluation was performed in 
13 patients and eight months evaluation in 12. Target segment 
diameter after high-dose acetylcholine infusion (10-4 mol/L) was 
-1.0 ± 7.38% and +0.10 ± 5.97% at four hours and eight 
months, respectively (p = 0.469).
In the three groups, vasoconstriction response to an 
acetylcholine dose of 10-4 mol/L was significantly higher 
compared to doses of 10-5 mol/L and 10-6 mol/L (Table 2). Table 
2 and Figure 1 show that the percent variation in diameter 
(endothelium-dependent vasomotor function) in all groups was 
similar at the two time points (p = 0.469). At four hours after 
stenting, the target segment presented an endothelial dysfunction 
that was maintained after eight months in all three groups. 
Response to nitroglycerin
In the three groups, endothelium-independent vasomotor 
response was similar at four hours and eight months. Target 
segment diameter increased from 2.18 ± 0.47 mm to 
2.53 ± 0.45 mm at four hours (p = 0.001) and from 2.10 ± 
0.41 mm to 2.42 ± 0.46 mm (p = 0.001) after eight months 
(Table 3 and Figure 2).
Mean target segment diameter for the three groups was 
2.71 ± 0.52 mm immediately after stenting, while patients 
were still under the effect of nitroglycerin. Four hours later, 
after the effect of nitroglycerin had subsided, a 19% reduction 
in diameter was observed, to 2.18 ± 0.47 mm (p = 0.001). 
After evaluation of endothelial function, these patients again 
received the same nitroglycerin dose and an increase in 
diameter was observed, to 2.54 ± 0.45 mm. There was 
endothelium-independent vasodilation, however of less 
intensity than that observed immediately after stenting. After 
administration of acetylcholine, the target segment’s mean 
diameter, with the same nitroglycerin dose, was smaller than 
the mean diameter observed immediately after stenting (p = 
0.001) (Figure 3).
Endothelial dysfunction, risk factors and use of medication
Endothelial dysfunction was not correlated with any of the 
variables evaluated among the three groups such as diabetes, 
arterial hypertension, dyslipidemia and smoking. The statin 
usage rate was very high for all three groups, 85%, 100%, 
76%, respectively.
Intravascular ultrasound evaluation of endothelial 
dysfunction and plaque volume (PV) in the target segment
PV was 58.23 ± 34.65 mm3 and 59.67 ± 38.88 mm3 
at four hours and eight months after stenting, respectively 
(p = 0.173). PV normalized by target segment length was 
4.34 ± 2.60 mm3/mm and 4.53 ± 2.94 mm3/mm four hours 
and eight months after stenting, respectively (p = 0.096). 
Taking into consideration the overall group of 39 patients, 
PV distally to the stent, at the target segment, was not 
correlated to endothelium-dependent vasomotor dysfunction 
as evaluated with acetylcholine (10-4 mol/L). No correlation 
was observed between PV normalized by segment length 
and vasomotor response to acetylcholine (10-4 mol/L), with a 
Pearson correlation coefficient of 0.17 [95% CI (-0.17 - 0.48)] 
four hours after stenting and 0.23 [95%CI (-0.11 - 0.52)] at 
eight months, respectively (Figure 4).
Discussion
Bare Metal Stent and vasomotor function
Caramori et al1 were pioneers in the evaluation of 
endothelial function in patients submitted to PCI with three 
techniques (balloon angioplasty, directional atherectomy and 
stenting). To evaluate endothelial function six months after PCI, 
those authors used intracoronary acetylcholine infusion. They 
observed more severe endothelial dysfunction with stenting 
as compared to other techniques.
Maier et al2 reported vasodilation in the proximal and distal 
portions of the stented segment (+8% and +11%, respectively) 
in response to exercise 10 months after stenting, showing 
normal coronary vasomotion. Monnink et al20 observed that 30 
patients with ischemia on the stress test had vasoconstriction in 
response to acetylcholine in the distal segment more frequently 
six months after stenting.
The conflicting findings reported by Maier et al2 and 
Caramori et al1 have been attributed to the different methods 
used to evaluate endothelial function (physical exercise and 
intracoronary infusion of acetylcholine). However, Gordon 
et al21 have concluded that the two methods are equivalent. 
Maier et al2 have also suggested that the variation could 
be explained by differences in the severity of coronary 
atherosclerosis between the small samples analyzed (12 
patients in the study by Caramori et al1 and 14 in the study 
by Maier et al2). To investigate this aspect, in this study we 
measured PV distally to the stent using IVUS. Contrary to 
the hypothesis raised by Maier et al2, we did not observe 
a relationship between PV and response to intracoronary 
infusion of acetylcholine. The three studies share the 
limitation of not having evaluated vasomotor endothelial 
function before stenting and not having evaluated the distal 
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Table 2 - Percent diameter variation in response to intracoronary acetylcholine infusion 
Group
4 hours 8 months
A6 A5 A4 A6 A5 A4
1
Mean -0.12 -0.06 -2.36 -0.14 -2.66 -4.63
SD 4.89 7.29 10.86 7.27 4.90 10.53
Minimum -6.66 -16.55 -21.91 -14.23 -8.43 -29.7
Maximum 9.08 8.79 13.76 11.64 8.16 9.49
2
Mean 0.11 -1.23 -5.98 -2.53 -1.45 -4.42
SD 4.34 3.91 12.62 6.79 7.81 14.64
Minimum -7.91 -8.40 -37.20 -21.87 -21.0 -33.7
Maximum 5.39 4.06 7.25 5.21 5.96 11.96
3
Mean 0.77 0.81 -1.00 -0.25 0.92 0.10
SD 4.66 6.38 7.38 4.31 3.80 5.97
Minimum -7.64 -10.04 -15.71 -9.99 -4.35 -11.9
Maximum 7.63 9.94 10.64 4.54 7.57 10.12
Total
Mean 0.25 -0.13 -3.02* -0.97 -1.06 -2.99†‡
SD 4.55 6.01 10.39 6.18 5.79 10.88
Minimum -7.91 -16.55 -37.20 -21.87 -21.0 -33.7
Maximum 9.08 9.94 13.76 11.64 8.16 11.96
A4 - 10-4 mol/L acetylcholine; A5 - 10-5 mol/L acetylcholine; A6 - 10-6 mol/L acetylcholine; * p = 0.022 (A4 vs. A5 and A6 – at 4 hours); SD - standard deviation, 
†p = 0.022 (A4 vs. A5 and A6 measurement at 8 months); ‡p = 0.469 (A4 at 4 hours vs. A4 at 8 months).
Figure 1 - Percent variation in diameter (endothelium-dependent vasomotor function).
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Table 3 - Diameter of target segment (mm): control (C), recontrol (RC) and after nitroglycerin intracoronary infusion (NTG) 
Group
4 hours 8 months
C RC NTG C RC NTG
1
Mean 2.17 2.19 2.50 2.01 1.99 2.24
SD 0.39 0.39 0.44 0.36 0.33 0.35
Minimum 1.52 1.50 1.70 1.60 1.60 1.85
Maximum 2.86 2.89 3.12 2.53 2.50 2.93
2
Mean 2.17 2.20 2.58 2.22 2.22 2.60
SD 0.48 0.48 0.44 0.48 0.51 0.49
Minimum 1.23 1.35 1.87 1.56 1.53 1.95
Maximum 3.12 3.28 3.45 3.00 2.98 3.29
3
Mean 2.21 2.21 2.53 2.06 2.07 2.40
SD 0.57 0.54 0.51 0.39 0.37 0.48
Minimum 1.46 1.46 1.81 1.49 1.53 1.60
Maximum 3.26 3.20 3.61 2.75 2.72 3.08
Total
Mean 2.18* 2.20 2.53† 2.10‡|| 2.09 2.42§
SD 0.47 0.46 0.45 0.41 0.41 0.46
Minimum 1.23 1.35 1.70 1.49 1.53 1.60
Maximum 3.26 3.28 3.61 3.00 2.98 3.29
C - control; RC – recontrol; NTG - nitroglycerin; SD - standard deviation, *p = 0.918 (control vs. recontrol at 4 hours); †p = 0.001 (NTG at 4 hours vs. control at 4 hours); 
‡p = 0.918 (control vs. recontrol at 8 months); §p = 0.001 (NTG 8 months vs. control 8 months); ||p = 0.015 (Control at 8 months vs. control at 4 hours).
Figure 2 - Groups in response to nitroglycerin.
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Figure 3 - 39 patients in response to nitroglycerin.
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segment with IVUS.Four hours after stenting, we observed 
endothelial dysfunction characterized by -3% vasoconstriction 
in response to a higher concentration of acetylcholine (A4) 
in the 15mm section distally from the stent. IVUS findings 
in this target segment reveal the presence of atherosclerotic 
plaque in all the sections evaluated. In fact, Mintz et al22 had 
already reported atherosclerotic plaque shown by IVUS in 
93.2% of angiographically normal reference segments. The 
finding of atherosclerotic plaque associated with underlying 
endothelium with normal vasomotor function has also been 
reported by Nishimura et al23. 
As Caramori et al1,  we employed the same methodology 
to evaluate endothelium-dependent vasomotor function. 
Nevertheless, different results were observed: those authors 
state that the PCI is implicated in long-term endothelial 
dysfunction, with stenting being associated with greater 
severity, while we do not believe that the endothelial 
dysfunction observed at eight months was caused by the 
stents, especially because it was already present four hours 
after stenting. 
The maintenance of endothelial dysfunction that we 
observed with BMS may be of clinical relevance when 
considering drug eluting stents24. Several reports have 
shown that DES may be associated with severe endothelial 
dysfunction7-9. This fact has led to improved technology 
associated to DES with biodegradable and biocompatible 
polymers14,15 and drugs with fewer side-effects on the 
endothelium13. There are recent new stents without polymers 
and drugs eluted directly into the face of the abluminal stent16.
Oral Sirolimus and vasomotor function
Among the oral drugs used to control vascular proliferative 
response after coronary angioplasty, the sirolimus showed the 
most promising results25-27. Arruda et al28 observed that patients 
with kidney transplant in a regular immunosuppression 
regimen who were submitted to angioplasty had only moderate 
in-stent intimal proliferation. Soon after that, the same group 
reported that the use of oral sirolimus was associated with a 
small amount of in-stent intimal proliferation29. On the other 
hand, the effect of oral sirolimus on coronary vasomotion 
had not been described. We employed oral sirolimus to 
control in-stent intimal proliferation, a measure that did not 
affect the status of endothelium-dependent and independent 
vasomotor function.
Limitations
Ethical considerations precluded us from testing coronary 
endothelial function in patients with severe stenosis before 
treating them with stenting. Epicardial coronary vessels with 
tight stenosis may occlude acutely with acetylcholine infusion. 
Therefore, we cannot be sure that the status of endothelial 
function four hours after the procedure had not been acutely 
modified by stenting. This may be the greatest limitation of 
this study. 
Also, these patients use to take a number of drugs that have 
beneficial effects on endothelial function, especially the statins. 
They are so effective on lowering cardiovascular events rate that 
it would be unethical to discontinue them, even temporarily. 
They may have attenuated endothelial dysfunction30,31.
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As to the relatively small sample size, it could be a concern 
because it was calculated based on the expected in-stent intimal 
response measured by IVUS. But this is unlikely, because most of 
the human coronary endothelial interventional studies typically 
include no more than a few dozen individuals and successfully 
detect differences between study groups32,33.
Conclusions
Endothelial function status was not affected by BMS 
stenting. Furthermore, even significantly lowering in-stent 
intimal hyperplasia, orally administered sirolimus did not affect 
coronary endothelial dependent and independent response.
Potential Conflict of Interest
No potential conflict of interest relevant to this article was 
reported.
Sources of Funding
This study was partially funded by CAPES.
Study Association
This article is part of the thesis of doctoral submitted 
by Rósley Weber Alvarenga Fernandes, from Universidade 
Federal de São Paulo.
Figure 4 - Correlation of PV with the response to acetylcholine.
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Erratum
In the original article “Impact of Stenting and Oral Sirolimus on Endothelium-Dependent and Independent 
Coronary Vasomotion”, consider as correct the keywords “Stents, coronary vessels, endothelium sirolimus”. 
April 2012
In the original article “The Influence of ACE Genotype on Cardiorespiratory Fitness of Moderately Active Young 
Men”, consider as correct the keywords “Angiotensin-converting enzyme; I/D polymorphism; VO2max, middle-
distance running”.
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